• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Akebia Therapeutics Inc.

    4/29/25 4:06:53 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKBA alert in real time by email
    DEFA14A 1 defacoverpage1.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _______________________
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. )
    _______________________
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    o    Preliminary Proxy Statement
    o    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    o    Definitive Proxy Statement
    x    Definitive Additional Materials
    o    Soliciting Material under §240.14a-12
    AKEBIA THERAPEUTICS, INC.
    (Name of Registrant as Specified In Its Charter)
    n/a
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    x    No fee required
    o    Fee paid previously with preliminary materials
    o    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
     

    Get the next $AKBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKBA

    DatePrice TargetRatingAnalyst
    6/4/2025$8.00Buy
    H.C. Wainwright
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    More analyst ratings

    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 48% to 109,400 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      6/11/25 5:16:36 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Adams Adrian was granted 35,700 shares, increasing direct ownership by 22% to 200,500 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      6/11/25 5:16:12 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wolf Myles was granted 35,700 shares, increasing direct ownership by 37% to 133,381 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      6/11/25 5:15:50 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

      Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

      3/28/24 10:46:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

      CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society of Nephrology (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, which included two trials in patients with dialysis-dependent chronic kidney disease (DD-CKD; INNO2VATE) and two trials in patients with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT). The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that c

      6/4/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of Akebia's common stock on May 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.03 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of th

      6/2/25 4:05:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

      CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The Jefferies Global Healthcare Conference will take place June 3-5, 2025, in New York City. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmace

      5/28/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Akebia Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00

      6/4/25 7:33:29 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

      Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

      4/28/25 8:36:09 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Akebia Therapeutics with a new price target

      Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

      4/1/25 9:03:14 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    SEC Filings

    See more
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      6/13/25 7:21:17 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Akebia Therapeutics Inc.

      10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:29:11 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:04:15 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care